Abstract
FcalphaRI as target for antibody therapy: Anti-tumor antibodies are promising therapeutics for cancer. Currently, all FDA-approved therapeutic antibodies are of the IgG class, which interact with IgG receptors (FcgammaR). In this project we examined the role of the IgA Fc receptor, FcalphaRI (CD89) in antibody therapy. Antibody-induced neutrophil migration was
... read more